摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-(4-chlorophenyl)-4H-furo<3,2-b>pyrrole-5-carboxylate | 71971-04-5

中文名称
——
中文别名
——
英文名称
2-(4-chlorophenyl)-4H-furo<3,2-b>pyrrole-5-carboxylate
英文别名
2-(4-chloro-phenyl)-4H-furo[3,2-b]pyrrole-5-carboxylic acid ethyl ester;2-(4-chloro-phenyl)-4H-furo[3,2-b]pyrrole-5-carboxylic acid ethyl ester;ethyl 2-(4-chlorophenyl)-4H-furo[3,2-b]pyrrole-5-carboxylate
2-(4-chlorophenyl)-4H-furo<3,2-b>pyrrole-5-carboxylate化学式
CAS
71971-04-5
化学式
C15H12ClNO3
mdl
——
分子量
289.718
InChiKey
ULEQQHNPISCAPV-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    4
  • 重原子数:
    20
  • 可旋转键数:
    4
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.13
  • 拓扑面积:
    55.2
  • 氢给体数:
    1
  • 氢受体数:
    3

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量
    • 1
    • 2

反应信息

点击查看最新优质反应信息

文献信息

  • Rigidified compounds for modulating heparanase activity
    申请人:InSight Biopharmaceuticals Ltd.
    公开号:US07795255B2
    公开(公告)日:2010-09-14
    Disclosed are novel rigidified compounds having a rhodanine-like residue and at least one aryl or heteroaryl residue linked to the rhodanine-like residue, whereby a core structure of these compounds, as defined in the specification, is characterized as having one or zero free-to-rotate bonds. Also disclosed are pharmaceutical compositions containing these rigidified compounds and uses thereof for modulating the activity of heparanase and hence in the treatment of heparanase-associated diseases and disorders, and uses thereof for modulating the activity of heparin-binding proteins and hence in the treatment of heparin-binding proteins-associated diseases and disorders as well as in the treatment of medical conditions that are at least partially treatable by rhodanine or a rhodanine analog.
    本发明揭示了一种新的刚性化合物,该化合物具有类似罗丹明的残基和至少一个与类似罗丹明残基相连的芳基或杂环芳基残基,其中这些化合物的核心结构,如规范中所定义的,其特征是具有一个或零个自由旋转键。本发明还揭示了含有这些刚性化合物的药物组合物,以及利用这些化合物调节肝素酶的活性,从而治疗肝素酶相关疾病和疾病的用途,利用这些化合物调节肝素结合蛋白的活性,从而治疗肝素结合蛋白相关疾病和疾病的用途,以及治疗至少部分可由罗丹明或罗丹明类似物治疗的医疗状况的用途。
  • Krutosikova, Alzbeta; Kovac, Jaroslav; Chudobova, Maria, Collection of Czechoslovak Chemical Communications, 1980, vol. 45, # 11, p. 2949 - 2957
    作者:Krutosikova, Alzbeta、Kovac, Jaroslav、Chudobova, Maria、Ilavsky, Dusan
    DOI:——
    日期:——
  • KRUTOSIKOVA A.; KOVAC J.; KRISTOFCAK FJ., COLLECT. CZECH. CHEM. COMMUN., 1979, 44, NO 6, 1979-1804
    作者:KRUTOSIKOVA A.、 KOVAC J.、 KRISTOFCAK FJ.
    DOI:——
    日期:——
  • KRUTOSIKOVA A.; KOVAC J.; CHUDOBOVA M.; ILAVSKY D., COLLECT. CZECH. CHEM. COMMUN., 1980, 45, NO 11, 2949-2957
    作者:KRUTOSIKOVA A.、 KOVAC J.、 CHUDOBOVA M.、 ILAVSKY D.
    DOI:——
    日期:——
  • RIGIDIFIED COMPOUNDS FOR MODULATING HEPARANASE ACTIVITY
    申请人:InSight Biopharmaceuticals Ltd.
    公开号:EP1846383A2
    公开(公告)日:2007-10-24
查看更多

同类化合物

顺式-六氢呋喃并[3,4-C]吡咯 甲基4-甲基-4H-呋喃并[3,2-b]吡咯-5-羧酸酯 氮杂环丁烷并[1,2-a]呋喃并[2,3-c]吡咯 夫沙瑞汀A 呋喃并吡咯甲酸 六氢-1H-呋喃并[3,4-c]吡咯 六氢-1H-呋喃并[3,4-C]吡咯 八氢-呋喃并[3,2-c]吡啶 乙基4,6-二氢-5H-呋喃并[2,3-c]吡咯-5-羧酸酯 6H-呋喃并[2,3-b]吡咯-5-羧酸甲酯 6-甲基-6H-呋喃并[2,3-b]吡咯-5-羧酸 6-甲基-6H-呋喃并[2,3-b]吡咯-5-甲酰肼 4H-呋喃并[3,2-b]吡咯-5-羧酸乙酯 4H-呋喃并[3,2-b]吡咯-5-羧酸,2-甲酰基-,甲基酯 4H-呋喃并[3,2-b]吡咯 4H-呋喃并[3,2-B!吡咯-5-羧酸甲酯 4-甲基呋喃[3,2-b]吡咯-5-羧酸乙酯 4-甲基-4H-呋喃并[3,2-b]吡咯 4-甲基-4H-呋喃并[3,2-B]吡咯-5-甲酸 365-苄基六氢-1H-呋喃[34-c]吡咯 3-溴-4H-呋喃并[3,2-b]吡咯-5-羧酸 3-溴-4H-呋喃并[3,2-b]吡咯-5-甲酸乙酯 2-苯基-4H-呋喃并[3,2-b]吡咯-5-羧酸 2-甲酰基-6-甲基-6H-呋喃并[2,3-b]吡咯-5-羧酸 2-甲酰基-4-甲基-4H-呋喃并[3,2-b]吡咯-5-羧酸甲酯 2-甲基-4H-呋喃并[3,2-b]吡咯-5-羧酸甲酯 2-甲基-4H-呋喃并[3,2-b]吡咯-5-羧酸乙酯 2-甲基-4H-呋喃并[3,2-b]吡咯-5-羧酸 2-溴-4H-呋喃并[3,2-b]吡咯-5-羧酸乙酯 2-溴-4H-呋喃并[3,2-B]吡咯-5-羧酸 2-(4-甲氧基苯基)-4H-呋喃并[3,2-b]吡咯-5-羧酸乙酯 2-(4-甲氧基苯基)-4H-呋喃并[3,2-b]吡咯-5-羧酸 2,3,3A,4-四氢-5H-呋喃并[3,2-b]吡咯-5-酮 1-(4H-呋喃并[3,2-b]吡咯-4-基)乙酮 1-(2-甲基-4H-呋喃并[3,2-b]吡咯-4-基)乙酮 (9ci)-1-甲基-1H-呋喃并[3,4-b]吡咯-4,6-二酮 (4-甲基-4H-呋喃并[3,2-b]吡咯-5-基)甲醇 (3aR,6aR)-4-乙酰基六氢-2H-呋喃并[3,2-b]吡咯-2-酮 5-(3-chloropropyl)hexahydro-1H-furo[3,4-c]pyrrole Methyl 2-[2-cyano-2-(methoxycarbonyl)vinyl]-6-methoxyfuro[2,3-b]pyrrole-5-carboxylate Methyl 6-methoxymethyl-2-(3,3,6,6-tetramethyl-1(2H),8(7H)-dioxo-3,4,5,6-tetrahydro-9H-xanthen-9-yl)furo[2,3-b]pyrrole-5-carboxylate methyl 2-cyano-6-(methoxymethyl)furo[2,3-b]pyrrole-5-carboxylate Methyl 2-(2,2-dicyanovinyl)-6-methoxymethylfuro[2,3-b]pyrrole-5-carboxylate (1R,5S,1'S)-1,5-dimethyl-8-phenylethyl-2-oxa-8-azabicyclo[3.3.0]octane-3,7-dione (1S,5R,1'S)-1,5-dimethyl-8-phenylethyl-2-oxa-8-azabicyclo[3.3.0]octane-3,7-dione {3-[2-(4-chloro-phenyl)-6-oxo-4-thioxo-6H-1-oxa-3b,5-diaza-cyclopenta[a]pentalen-5-yl]-propyl}-phosphonic acid diethyl ester methyl 4-(3,4-dichlorobenzyl)-2-formylfuro[3,2-b]pyrrole-carboxylate (3aR,6aS)-5-benzyl-3a,6a-dimethyltetrahydro-1H-furo[3,4-c]pyrrole-1,3(3aH)-dione (1R,2R,6R,8R,15S)-10,14-aza-4,4-dimethyl-11-oxo-1-mesyloxy-3,5,7-trioxa-tetracyclo[7.6.0.02,6.010,15]pentadecane 5-methyl-1,3-bis(3-oxobutyl)dihydro-1H-furo[3,4-c]pyrrole-4,6(5H,6aH)-dione